Christelle Dousset

Nantes, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

Journal: Leukemia
Published: September 18, 2025

VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.

VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.

Journal: Leukemia
Published: September 20, 2024

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Journal: HemaSphere
Published: April 16, 2024

Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.

Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.

Journal: Haematologica
Published: September 21, 2023

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.

Journal: Blood
Published: June 23, 2023

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.

Journal: Blood
Published: February 24, 2023

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.

Journal: Haematologica
Published: August 11, 2021

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Journal: Frontiers in oncology
Published: November 09, 2018

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Journal: Haematologica
Published: January 07, 2017

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

Journal: British journal of haematology
Published: August 16, 2016

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

Journal: British journal of haematology
Published: July 30, 2016

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.

Journal: Blood
Published: June 03, 2016
Showing 1-12 of 17

Last Updated: 09/26/2026